Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA Approves Rhapsido for People With Hives Triggered by Skin Rubbing

8 October 2026 · By · Wire by Fusion42

Published

8 October 2026

Topic

operational-macro

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at webmd.com →

◆ Verified

Fusion42 · 9 October 2026 · Fusion42 review

The FDA has approved Rhapsido, a new treatment for people who experience hives triggered by skin rubbing.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

Healthcare founders in drug development for skin conditions face a newly cleared regulatory path for treatments addressing physical urticaria. This approval opens a market gap you can now target with novel therapies.

◆ Coverage

1 source · 8 Oct 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryFDA-approvaldrug-launchhives-treatmentskin-condition